Impact of Anamorelin with unresectable pancreatic, gastric and colorectal cancer patients for a quality of life, skeletal muscle index and malnutritio
- Conditions
- Pancreatic cancer Gastric cancer Colorectal cancer
- Registration Number
- JPRN-UMIN000045611
- Lead Sponsor
- Asahikawa Medical University Department of Medicine, Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 194
Not provided
1. Patients who receives Anamorelin treatment 1) under 20 years old 2) Patients with severe cardiac disease 3) Patients with severe liver disease (Child-Pugh B or C) 4) Patients with severe psychologic disease 5) Patients who is taking medications as follows; Clarithromycin, Indinavir, Itraconazole, Nelfinavir, Saquinavir, Telaprevir, Voriconazole, Ritonavir-containing agent or Cobicistat-containing agent 6) Unable to oral intake due to gastrointestinal occlusion or other organic gastrointestinal disorders 7) Unable to take part in this study due to other severe complication 8) Disqualified to take part in this study judged by attending/primary doctors 9) Patients with congestive heart failure, myocardial infarction, angina pectoris or severe cardiac conduction abnormalities 2. Patients who does not receive Anamorelin treatment 1) under 20 years old 2) Patients with severe cardiac disease 3) Patients with severe liver disease (Child-Pugh B or C) 4) Patients with severe psychologic disease 5) Unable to oral intake due to gastrointestinal occlusion or other organic gastrointestinal disorders 6) Unable to take part in this study due to other severe complication 7) Disqualified to take part in this study judged by attending/primary doctors When the patient is determined not to qualify taking part in this study after the registration, the patients will be excluded from the study immediately.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in QOL between non-Anamorelin usage and Anamorelin usage patients in 24 weeks (assessed by EORTC QLQ-C30)
- Secondary Outcome Measures
Name Time Method